CSIMarket
 
Abbvie inc   (ABBV)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 
Price: $107.9100 $1.02 0.954%
Day's High: $108.55 Week Perf: -0.31 %
Day's Low: $ 107.14 30 Day Perf: 2.73 %
Volume (M): 8,208 52 Wk High: $ 113.41
Volume (M$): $ 885,725 52 Wk Avg: $97.54
Open: $107.49 52 Wk Low: $79.11



 Market Capitalization (Millions $) 192,835
 Shares Outstanding (Millions) 1,787
 Employees 30,000
 Revenues (TTM) (Millions $) 45,804
 Net Income (TTM) (Millions $) 4,622
 Cash Flow (TTM) (Millions $) -31,475
 Capital Exp. (TTM) (Millions $) 798

Abbvie Inc
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.


   Company Address: 1 North Waukegan Road North Chicago 60064 IL
   Company Phone Number: 932-7900   Stock Exchange / Ticker: NYSE ABBV
   ABBV is expected to report next financial results on April 22, 2021.


Customers Net Income grew by ABBV's customers Net margin grew to

19.03 %

3.63 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GILD        2.7% 
BIIB        0.8% 
AMGN        2.72% 
ABT        2.85% 
LLY        2.58% 
BMY        4.55% 
• View Complete Report
   



Coca Cola Femsa Sab De Cv

EPS $0.03, Sales Weak

In the fourth quarter of 2020 earnings season Coca Cola Femsa Sab De Cv eps of $0.03 per share compared to $0.00 a year ago and from $0.00 per share from the previous quarter.

Sales declined in double digits by -10.47% to $9.23 billions from $10.31 billions in the same quarter a year ago and sequentially from $0.00 millions.
Coca Cola Femsa Sab De Cv reported earnings of $521.00 millions and Sales of $9.23 billions for the fiscal year 2020.

Company reported earnings per share of $0.03 compared to $0.00 in the previous fiscal year, while Sales deteriorated by -10.47 % from $10.31 billions a year ago.

Vnue Inc

Break-even, Topline Tumbles

In the most recent fiscal period Vnue Inc reached break-even of $0.00 per share compared to $-0.03 a year ago and from $-0.01 per share from the previous quarter.

Sales fell sharply to $0.00 millions from $0.01 millions in the same quarter a year ago and sequentially from $0.00 millions.
Vnue Inc reported net loss of $-4.55 millions and Sales of $0.02 millions for the fiscal year 2020.

Company reported break-even compared to $0.00 in the previous fiscal year, while Sales deteriorated by -89.1 % from $0.21 millions a year ago.

Levi Strauss and Co

Levi Strauss And Co announced fiscal period ending Feb 28 2021 operating surplus of $177.123 millions

Sales and earnings fell in sympathy in the fiscal period ending Feb 28 2021, where earnings decreased by -5.41% to $0.35 per share and revenue by -13.31% year on year. Revenue were at $1.31 billions compared to $1.51 billions in the same quarter a year ago.

From the preceding quarter, eps more than doubled by 145.72 % from $0.14 per share and Sales decreased by -5.79% from $1.39 billions.

Pricesmart inc

Earnings and Sales Increased

Pricesmart Inc had fiscal second quarter of 2021 Sales increase of 3.4% to $937.57 millions from $906.74 millions from the same quarter a year ago, company grew eps by 8.24 % to $0.92, from $0.85 in the prior year quarter.

In the previous quarter company realized Sales of $877.43 millions and bottom line of $0.90 per share.

Wd 40 Company

Sales and Eps Grew in Double Digits

Company reported double digit Sales and earnings growth in the second quarter of 2021. Sales were at $111.91 millions up by 11.85% year on year and deteriorated by -10.16% quarter on quarter, while income increased by 19.23 % to $1.24, sequentially income faded by -27.91%.







 

Abbvie Inc 's Segments
 
HUMIRA
 Segment    64.66 % of total Revenue
Kaletra
 Segment    2.98 % of total Revenue
AndroGel
 Segment    3.14 % of total Revenue
Lupron
 Segment    3.56 % of total Revenue
Synthroid
 Segment    3.33 % of total Revenue
Other
 Segment    5.5 % of total Revenue
Synagis
 Segment    1.65 % of total Revenue
Sevoflurane
 Segment    2.16 % of total Revenue
Creon
 Segment    2.85 % of total Revenue
VIEKIRA
 Segment    8.32 % of total Revenue
Dyslipidemia products
 Segment    0.76 % of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Abbvie Inc does not provide revenue guidance.

Earnings Outlook
Wd 40 Company does not provide earnings estimates.

 
Geographic Revenue Dispersion
United States 56.37 %
Japan 3.02 %
Germany 5.38 %
Canada 2.86 %
The Netherlands 5.04 %
Italy 2.25 %
All Other Countries 17.01 %
Brazil 2.26 %
Spain 2.78 %
France 3.04 %


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TBNK's Profile

Stock Price

TBNK's Financials

Business Description

Fundamentals

Charts & Quotes

TBNK's News

Suppliers

TBNK's Competitors

Customers & Markets

Economic Indicators

TBNK's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071